Assays for measurement of TNF antagonists in practice. Issue 4 (8th March 2016)

• Record Type: Journal Article
• Authors: Vande Casteele, Niels
• Is Part Of: Frontline gastroenterology. Volume 8:Issue 4(2017)
• Page Start: 236
• Page End: 242
• Publication Date: 2016-03-08
• Subjects: INFLIXIMAB -- INFLAMMATORY BOWEL DISEASE -- CROHN'S DISEASE -- ULCERATIVE COLITIS; Gastroenterology -- Periodicals; 616.33005
• DOI: 10.1136/flgastro-2016-100692
• Languages: English
• ISSNs: 2041-4137

Abstract

Abstract : Tumour necrosis factor (TNF) antagonist drug exposure is correlated with clinical, endoscopic and pathophysiological outcomes during induction and maintenance therapy. Measuring drug concentrations is therefore a useful tool when treating to target and optimising therapy. One of the main factors leading to suboptimal drug exposure is the formation of antidrug antibodies (ADAs), due to an immunogenic reaction of the immune system towards the non-self protein. The development of ADA does pose important concerns for drug efficacy and for safety as ADAs have been associated with acute infusion reactions, hypersensitivity reactions and serum sickness. Various assays exist to measure serum drug and ADA concentrations, either offered as a service in a specialised laboratory or commercially available as a kit. It is unclear how the performance of these assays relates to each other, until recently various comparative studies were carried out. The majority of these studies show that indeed a good correlation exists between the assays that measure drug, but that absolute concentrations can differ across tests. This is particularly relevant in clinical practice when a specific threshold or drug concentration range is targeted. For ADA assays, drug sensitivity or the ability of the assay to measure ADA in the presence of drug remains an important issue, especially for drugs with a higher dosing frequency. In addition, standardisation across ADA assays is difficult, making it hard to compare quantitative or semiquantitative (low/medium/high) results across assays and across studies.